Hangzhou Tigermed Consulting Co., Ltd.
Hangzhou Tigermed Consulting Co., Ltd. (HNGZY) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for Hangzhou Tigermed Consulting Co., Ltd. (HNGZY), featuring income statements, balance sheets, and cash flow data.
Hangzhou Tigermed Consulting Co., Ltd. (HNGZY) Income Statement & Financial Overview
View the income breakdown for Hangzhou Tigermed Consulting Co., Ltd. HNGZY across both annual and quarterly reports.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $1.54B | $1.71B | $1.69B | $1.65B |
| Cost of Revenue | $1.26B | $1.07B | $1.03B | $1.03B |
| Gross Profit | $271.73M | $637.23M | $661.95M | $620.42M |
| Gross Profit Ratio | $0.18 | $0.37 | $0.39 | $0.38 |
| R&D Expenses | $66.29M | $47.40M | $58.78M | $63.91M |
| SG&A Expenses | -$354.11M | $542.77M | $237.31M | $234.17M |
| Operating Expenses | $692.31M | $239.31M | $296.76M | $305.83M |
| Total Costs & Expenses | $1.96B | $1.31B | $1.33B | $1.34B |
| Interest Income | $0.00 | $0.00 | $26.65M | $0.00 |
| Interest Expense | $0.00 | $0.00 | $5.81M | $0.00 |
| Depreciation & Amortization | $0.00 | -$61.41M | $90.19M | $46.26M |
| EBITDA | -$288.35M | $336.52M | $379.63M | $352.86M |
| EBITDA Ratio | -$0.19 | $0.20 | $0.22 | $0.21 |
| Operating Income | -$420.58M | $397.93M | $365.19M | $314.59M |
| Operating Income Ratio | -$0.27 | $0.23 | $0.22 | $0.19 |
| Other Income/Expenses (Net) | -$2.03M | -$954682.00 | -$37.46M | $47.77M |
| Income Before Tax | -$422.60M | $396.97M | $283.63M | $362.36M |
| Income Before Tax Ratio | -$0.28 | $0.23 | $0.17 | $0.22 |
| Income Tax Expense | $32.70M | $51.42M | $82.72M | $49.79M |
| Net Income | -$408.29M | $320.58M | $257.78M | $235.07M |
| Net Income Ratio | -$0.27 | $0.19 | $0.15 | $0.14 |
| EPS | -$0.47 | $0.37 | $0.30 | $0.27 |
| Diluted EPS | -$0.47 | $0.37 | $0.30 | $0.27 |
| Weighted Avg Shares Outstanding | $862.007M | $864.95M | $864.95M | $872.44M |
| Weighted Avg Shares Outstanding (Diluted) | $862.007M | $864.95M | $864.95M | $872.44M |
The company's financials show resilient growth, with revenue advancing from $1.65B in Q1 2024 to $1.54B in Q4 2024. Gross profit remained healthy with margins at 18% in Q4 2024 compared to 38% in Q1 2024. Operating income hit -$420.58M last quarter, sustaining a consistent -27% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$288.35M. Net income dropped to -$408.29M, while earnings per share reached -$0.47. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan